Every 8-K that Lumexa Imaging Holdings, Inc. (LMRI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LMRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LMRI filings page.
Lumexa Imaging Holdings, Inc. reported second quarter 2026 results and updated its full year 2026 outlook. Total revenues were $264.2 million, up from $251.4 million a year earlier, driven by higher net patient service revenue and management fee and other revenue.
The company generated net income of $2.7 million, compared with a net loss of $7.2 million in Q2 2025. Adjusted EBITDA was $56.4 million, essentially in line with $56.3 million a year ago, while adjusted diluted EPS rose to $0.20 from $0.08. Outpatient volumes increased, with consolidated total procedures up to 617,722 and advanced procedures rising faster than overall volumes.
For the first six months of 2026, Lumexa Imaging posted net income of $4.5 million versus a loss of $14.9 million in the prior-year period and generated $35.7 million of cash from operating activities, compared with cash used of $11.9 million a year earlier. At June 30, 2026, total assets were $1.81 billion, total liabilities $1.19 billion, and equity $615.1 million.
Lumexa Imaging Holdings, Inc. has amended its main debt facilities through an updated credit agreement for its subsidiaries. The new structure includes a secured term loan of approximately $823 million, called the Replacement Term Loan, and a secured revolving credit facility of $250 million.
Both facilities bear interest at the borrowers’ option at SOFR plus 2.50% or the Prime Rate plus 1.50%. The Replacement Term Loan matures in December 2032, while the Amended Revolving Credit Facility matures in December 2030, extending the company’s debt maturity profile.
The agreement imposes restrictive covenants on subsidiary actions such as incurring additional debt and paying dividends, and introduces a financial covenant if revolving exposure exceeds 40% of the revolver’s principal. In that case, Lumexa’s consolidated net leverage ratio must not exceed 7.50 to 1, with standard lender remedies available after an event of default.
Lumexa Imaging Holdings, Inc. reported results of its 2026 Annual Meeting of Stockholders. Stockholders elected three Class I directors—Lee Cooper, Brian Regan and Caitlin Zulla—to serve until the 2029 annual meeting.
As of the April 13, 2026 record date, 96,110,039 common shares were entitled to vote. Lee Cooper received 87,523,628 votes for and 3,328,050 withheld, Brian Regan received 80,044,532 for and 10,807,146 withheld, and Caitlin Zulla received 87,156,663 for and 3,695,015 withheld, with 826,898 broker non-votes for each. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 with 91,555,829 votes for, 66,858 against and 55,889 abstentions.
Lumexa Imaging Holdings, Inc. reported a first-quarter 2026 profit and reiterated its full-year 2026 guidance. Total revenues rose to $252.5M from $245.0M, driven by higher outpatient imaging volumes and a greater mix of advanced procedures.
Net income improved to $1.7M, or $0.02 per diluted share, compared with a net loss of $7.7M, or $(0.11) per share, a year earlier. Adjusted EBITDA was stable at $51.2M, while adjusted diluted earnings per share increased to $0.18 from $0.04. System-wide total procedures grew, with advanced procedures expanding faster than overall volumes, supporting management’s view of sustained, profitable growth.
Lumexa Imaging Holdings, Inc. reported that on April 8, 2026 it held a meeting and site visit where it reiterated its previously disclosed full year 2026 guidance. The company stated this information is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act unless specifically designated or incorporated by reference.
Lumexa Imaging Holdings, Inc. reported preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025 and reiterated its full-year 2026 guidance. Full-year 2025 total revenues rose to $1,023,081 thousand from $948,869 thousand, while net loss narrowed to $47,104 thousand from $94,099 thousand. Adjusted EBITDA increased to $230,154 thousand from $200,839 thousand, reflecting stronger operating performance. Basic and diluted loss per share improved to $0.66 from $1.35. Outpatient volumes grew, with consolidated total procedures up 4.6% for 2025 and consolidated advanced procedures up 7.8%. The company strengthened its balance sheet: cash and cash equivalents increased to $58,828 thousand from $26,131 thousand, and long-term debt (less current maturities) declined to $819,029 thousand from $1,185,080 thousand, supported by initial public offering proceeds of $434,750 thousand.
Lumexa Imaging Holdings, Inc. released preliminary, unaudited fourth quarter and full year 2025 results and issued 2026 guidance. For 2025, GAAP net loss was $43,768 thousand, improving from $94,099 thousand in 2024, while Adjusted EBITDA rose to $229,029 thousand from $200,839 thousand. Fourth quarter 2025 Adjusted EBITDA was $62,625 thousand, up from $53,742 thousand a year earlier, with management citing expected Adjusted EBITDA growth of at least 14%. System-wide total procedures reached 3,972,228 in 2025, with advanced procedures growing and PET volumes up 17.0% on a consolidated basis and 13.5% system-wide. The company highlights expansion of de novo centers, one acquisition, new joint venture partnerships, and early adoption of AI-powered breast arterial calcification assessments as drivers of growth.
Lumexa Imaging Holdings, Inc. reported that its Chief Legal Officer and Corporate Secretary, Julie Szeker, submitted her resignation effective March 13, 2026. The company stated that her resignation is not due to any disagreement over operations, policies or practices and has begun a search for a successor.
Under a transition letter agreement, Ms. Szeker will receive a $450,000 transition payment and up to 12 months of subsidized healthcare coverage, subject to a release of claims and compliance with the agreement. She will also receive an annual bonus of $250,000 related to 2025 performance, payable at the same time as bonuses to other employees.
Lumexa Imaging Holdings, Inc. disclosed that its subsidiaries entered into an amended credit agreement led by Barclays Bank PLC. The agreement provides a secured term loan facility of $825 million maturing in December 2032 and a secured revolving credit facility of $250 million maturing in December 2030. Both facilities bear interest at the borrowers’ option at SOFR plus 3.00% or the Prime Rate plus 2.00%, with potential rate reductions on the revolver if certain senior secured net leverage ratios are met. The facilities are guaranteed by substantially all wholly owned subsidiaries and secured by substantially all of their assets, and include restrictive covenants and a financial covenant requiring a consolidated net leverage ratio not exceeding 7.50 to 1 if revolving borrowings exceed 40% of the revolver commitment at a quarter-end.
Lumexa Imaging Holdings, Inc. completed its initial public offering, selling 25,000,000 shares of common stock at a price of $18.50 per share. The company plans to use the net proceeds to repay a portion of its borrowings under a secured term loan facility with Barclays Bank PLC and for working capital, capital expenditures and other general corporate purposes.
In connection with becoming a public company, Lumexa appointed four new directors to staggered board classes, entered into indemnification agreements with all directors and executive officers, and put into effect its amended and restated certificate of incorporation and bylaws, consistent with descriptions in its IPO prospectus.